Osteoarthritis (OA) belongs to diseases with high comorbidity and most frequently concurrent with obesity, diabetes mellitus (DM), hypertension, and other cardiovascular diseases (coronary heart disease, atherosclerosis), gastrointestinal tract diseases, and chronic diseases of the lung and kidney. Irrational treatment of OA in the presence of comorbidity and without considering characteristics of drug interactions leads to a pronounced increase in the number of adverse reactions (ARs) and to aggravation of the course of all concomitant diseases. From this point of view, therapy seems to be relevant when the latter involves drugs that have both symptom- and structure-modifying properties and have a high safety profile.Objective: to compare the safety of alternating and standard treatment regimens with Alflutop® in patients with knee OA.Patients and methods. 130 patients were enrolled in the trial who had Kellgren-Lawrence Grade II–III primary tibiofemoral knee OA with pain intensity on walking ≥40 mm on a visual analogue scale and who needed to take nonsteroidal anti-inflammatory drugs (≥30 days in the previous 3 months). The patients were randomized into two groups: Group 1 was prescribed Alflutop® 1.0 ml intramuscularly (IM) daily for 20 days (a standard regimen); Group 2 was given 2 ml IM every other day (a total of 10 injections) (an alternating regimen). The duration of follow-up was 14 weeks. The safety of Alflutop® was evaluated by the incidence of ARs and serious ARs (SARs) varying in severity according to medical records, laboratory tests, physical examination, assessment of a patient' vital signs, and electrocardiography (ECG). The patients were examined at the beginning, at the end, and 1 month after therapy.Results and discussion. No SARs were recorded during the study period and follow-up. There were 10 ARs in the group of patients receiving Alflutop® in the standard regimen and 19 ARs in the other group (the alternating regimen). All ARs corresponded to mild and moderate severity, were unassociated with the test drug, and resolved by the end of the follow-up. 12-lead ECG identified only clinically insignificant abnormalities in the patients of both groups. Patients without DM displayed no clinically significant increase in glucose levels. Those with DM had no increased glycemia tendency. Biochemical studies in both groups revealed only clinically insignificant abnormalities, the frequency of which was insignificant.Conclusion. This study has confirmed the comparable high safety of Alflutop® in both standard and alternative therapy regimens. It has also shown that the drug has a good safety profile and can be recommended for wide clinical application in any use regimen: 1 ml daily (a total of 20 injections) or 2 ml every other day (a total of 10 injections).
The results of a preliminary analysis of the relationship between the short-term impact of air pollution exposure on hospitalizations associated with COVID-19 in Tomsk, Russia are presented. The statistical data on air pollution and COVID-19 associated hospitalization were collected and analyzed for the period from March 16, 2022 to April 14, 2022. This period corresponds to a flat plateau of confirmed COVID-19 cases after the main pandemic wave in 2022 in Tomsk and the Tomsk region which were associated with omicron strain of SARS-CoV-2. It was found that all representative peaks in a graph of daily hospitalizations coincide with the peaks in graphs of measured levels of air pollution. The increase in hospitalizations occurred on the same days when air pollution levels increased, or with a slight lag of 1-2 days. This allows us to tentatively conclude that air pollution has a quick effect on infected persons and may provoke an increase in symptoms and severity of the disease. Further detailed research is required.
The results of calculations of meteorological parameters and atmospheric air quality during abnormally cold weather (T below -20 o C) in Tomsk are presented. These results were obtained using a complex of WRF/CAMx models. The calculation results are compared with observations of ultrasonic meteo stations and temperature profiler of the Joint Usage Centre (JUC) «Atmosphere» and observations of TOR-station of the IAO SB RAS. The adapted Common Air Quality Index (Citeair II project, supported by the EU) calculated by hourly predicted concentrations is used to evaluate the level of atmospheric pollution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.